T Cell News and Research

Latest T Cell News and Research

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

NanoViricides, Inc., reports that its anti-Herpes drug candidates demonstrated significant efficacy in the recently completed cell culture studies. The studies were performed in the laboratory of Dr. Ken Rosenthal at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

16 Aug 2010

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development.

16 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

CTI announces EMEA's validation of expanded PIP for pixantrone

Cell Therapeutics, Inc. announced today that it has received notice that the European Medicines Agency has validated the expanded Pediatric Investigation Plan that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).

16 Aug 2010

Scientists identify genes associated with aggressive breast cancer

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment strategies for patients.

16 Aug 2010

Researchers pace embryonic heart with laser

Scientists at Case Western Reserve University and Vanderbilt University found that pulsed light can pace contractions in an avian embryonic heart, with no apparent damage to the tissue. The work, "Optical pacing of the embryonic heart," will be published in the advanced online issue of Nature Photonics on Aug. 15, 2010.According to the scientists, this non-invasive device may prove an effective tool in understanding how environmental factors that alter an embryo's heart rate lead to congenital defects. It may also lead to investigations of cardiac electrophysiology at the cellular, tissue and organ levels, and possibly the development of a new generation of pacemakers.

16 Aug 2010

MeCP2 protein regulates properties of psychostimulant drugs: Research

When a certain protein is mutated or missing, symptoms of the neurodevelopmental disorder Rett syndrome arise, causing a gradual loss of brain function during early development.This fact led Duke University Medical Center researchers to test a theory that the protein might also contribute to nerve-cell connection (synapse) changes in a fully formed adult mouse brain when exposed to psychostimulant use.

16 Aug 2010

Inovio Pharmaceuticals 2010 second quarter net loss decreases

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010.Total revenue was $1.1 million and $2.5 million for the three and six months ended June 30, 2010, compared to $2.5 million and $2.9 million for the three and six months ended June 30, 2009, respectively.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Adverse effects in childhood lead to immune impairment later in life

The emotional pains we suffer in childhood can lead to weakened immune systems later in life, according to a new study.Based on this new research, the amount of this immune impairment even enhances that caused by the stress of caregiving later in life."What happens in childhood really matters when it comes to your immune response in the latter part of your life," explained Janice Kiecolt-Glaser, professor of psychology and psychiatry at Ohio State University. She explained her work at the annual meeting of the American Psychological Association in San Diego.

16 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

Researchers discover genetic alterations responsible for Kabuki syndrome

Using a new, rapid and less expensive DNA sequencing strategy, scientists have discovered genetic alterations that account for most cases of Kabuki syndrome, a rare disorder that causes multiple birth defects and mental retardation. Instead of sequencing the entire human genome, the new approach sequences just the exome, the 1-2 percent of the human genome that contains protein-coding genes.

16 Aug 2010

CD31 positive cells have potential for treating peripheral artery disease: Research

Isolating cells from a patient's blood or bone marrow that nourish blood vessels may be a safer and less arduous route to treatment of cardiovascular disease than obtaining rare stem cells, according to research from Emory University School of Medicine. In recent clinical trials, doctors in several countries have tested the ability of a patient's bone marrow cells to repair damage, such as heart attacks and peripheral artery disease, created by problems of blood flow.

16 Aug 2010

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010.

13 Aug 2010

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair. The study is published in the Aug. 13 edition of the journal Molecular Cell.

13 Aug 2010

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

T Cell News and Research

Latest T Cell News and Research

NanoViricides' anti-Herpes drug candidates demonstrate significant efficacy in cell culture studies

ISCT partners with leading companies in cell therapy regenerative medicine market to drive clinical development

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

CTI announces EMEA's validation of expanded PIP for pixantrone

Scientists identify genes associated with aggressive breast cancer

Researchers pace embryonic heart with laser

MeCP2 protein regulates properties of psychostimulant drugs: Research

Inovio Pharmaceuticals 2010 second quarter net loss decreases

New T cell engineering approach can improve success rate of immune-cell therapies

Adverse effects in childhood lead to immune impairment later in life

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Researchers discover genetic alterations responsible for Kabuki syndrome

CD31 positive cells have potential for treating peripheral artery disease: Research

Soligenix’s net loss for second-quarter 2010 decreases to $1,577,000

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

Merlin protein controls adult cell activity to cause liver cancer

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Newsletters you may be interested in